Diabetic Nephropathy
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs…
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The current standard of care fails to halt the frequent progression of DN to kidney…
Clarivate Epidemiology’s coverage of diabetic nephropathy (DN) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report…
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs…
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The current standard of care fails to halt the frequent progression of DN to kidney…
Diabetic nephropathy, also referred to as diabetic kidney disease, is a common complication of diabetes. The diabetic nephropathy drug market comprises a wide variety of antidiabetic and…
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. Current standard of care fails to halt the frequent progression of DN to kidney…
Patients with type 2 diabetes (T2D) and nephropathy, also known as diabetic nephropathy (DN), are at significant risk of developing end-stage renal disease (ESRD), a condition associated with…
The diabetic nephropathy (DN) market is poised to expand rapidly over the next decade as late-stage therapies reach the G7 markets. These agents represent the first potential disease-modifying…
Diabetic nephropathy (DN) refers to kidney disease caused by diabetes. DN is a leading cause of chronic kidney disease (CKD), and is associated with high morbidity, mortality, and cost. Use of…
This third-time report focuses on the management of diabetic nephropathy (DN) in the United States. The U.S. market for DN drugs is poised to expand owing to the growing size of the DN patient…
This second-time report focuses on the management of diabetic nephropathy (DN) in the United States. The U.S. market for DN drugs is poised to expand owing to the growing size of the DN patient…